FDA says anemia drug peginesatide is comparable to other treatments

12/5/2011 | Reuters

FDA drug reviewers said Affymax's peginesatide, a treatment for anemia in dialysis patients with chronic kidney disease, performs comparably with Amgen's Epogen and Aranesp in maintaining an ideal hemoglobin level. However, reviewers voiced concern about peginesatide's safety profile. An FDA panel is set to review the drug Wednesday, and the agency's final decision is anticipated by March 27.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ